{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T11:52:50Z","timestamp":1794225170425,"version":"4.8.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T00:00:00Z","timestamp":1669939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T00:00:00Z","timestamp":1669939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Henoch-Sch\u00f6nlein purpura (HSP) with refractory gastrointestinal (GI) symptoms is always difficult to handle because of its resistance to supportive therapies and glucocorticoid. This study aimed to evaluate the efficacy of hemoperfusion (HP) and intravenous immunoglobulins (IVIG) therapies in this population.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Sixty-four HSP patients with refractory GI involvement (R-GI group) and 64 cases with mild GI symptoms (control group) were retrospectively analyzed in our center from March 2016 to October 2019. In R-GI group, 42 cases (subgroup A) were treated with IVIG and steroid, 13 cases (subgroup B) used HP and steroid, 9 cases (subgroup C) executed a combination of IVIG, HP and steroid. Demographic characteristics, clinical features, laboratory indexes and treatment outcomes were recorded. <jats:italic>t<\/jats:italic>-test, One-way ANOVA, Mann-Whitney <jats:italic>U<\/jats:italic> test, and multivariate logistic regression were used in comparing differences among subgroups and predicting independent risk factors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Compared with the control group, R-GI cases experienced higher risk of renal involvement (<jats:italic>P<\/jats:italic>\u2009=\u20090.000), more steroid exposure (<jats:italic>P<\/jats:italic>\u2009=\u20090.000), six times expenses (<jats:italic>P<\/jats:italic>\u2009=\u20090.000) and 2.3 times length of hospitalization (<jats:italic>P<\/jats:italic>\u2009=\u20090.000). The independent risk factors of R-GI group were elevated neutrophils (OR 1.250 [95% CI 1.130-1.383]) and the percentage of B lymphocytes (OR 1.100 [95% CI 1.026-1.179]) as well as decreased IgG (OR 0.847 [95% CI 0.732-0.98]). In R-GI group, increased age (OR 1.039 [95% CI 1.016-1.062]) and IgM (OR 5.994 [95% CI 1.403-27.611]) were verified to be risk factors of HSP nephritis. All three subgroups could alleviate the symptoms effectively. Compared with those in subgroup A, patients in subgroup B were elder (<jats:italic>P<\/jats:italic>\u2009=\u20090.004), had less relapse (<jats:italic>P<\/jats:italic>\u2009=\u20090.002), steroid exposure (<jats:italic>P<\/jats:italic>\u2009=\u20090.033) and expenses (<jats:italic>P<\/jats:italic>\u2009=\u20090.031), more significant decrease of WBC (<jats:italic>P<\/jats:italic>\u2009=\u20090.026) after treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The HSP with refractory GI involvement had much higher risk of medical burden and renal involvement. Both IVIG and HP therapies could ameliorate refractory GI symptoms efficiently. HP therapy tended to reduce the relapse, costs and steroid exposure in its audiences who were cooperated and with stable hemodynamics, while IVIG had better use in younger children.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12887-022-03709-0","type":"journal-article","created":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T10:27:59Z","timestamp":1669976879000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Hemoperfusion and intravenous immunoglobulins for refractory gastrointestinal involvement in pediatric Henoch-Sch\u00f6nlein purpura: a single-center retrospective cohort study"],"prefix":"10.1186","volume":"22","author":[{"given":"Xiaolu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruochen","family":"Che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haisheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guixia","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songming","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aihua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,2]]},"reference":[{"issue":"8","key":"3709_CR1","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.paed.2011.11.013","volume":"22","author":"G Smith","year":"2012","unstructured":"Smith G. Management of Henoch\u2013Sch\u00f6nlein purpura. Paediatr Child Health. 2012;22(8):327\u201331. https:\/\/doi.org\/10.1016\/j.paed.2011.11.013.","journal-title":"Paediatr Child Health"},{"issue":"9341","key":"3709_CR2","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/s0140-6736(02)11279-7","volume":"360","author":"JM Gardner-Medwin","year":"2002","unstructured":"Gardner-Medwin JM, Dolezalova P, Cummins C, Southwood TR. Incidence of Henoch-Sch\u00f6nlein purpura. Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet. 2002;360(9341):1197\u2013202. https:\/\/doi.org\/10.1016\/s0140-6736(02)11279-7.","journal-title":"Lancet."},{"issue":"25","key":"3709_CR3","doi-asserted-by":"publisher","first-page":"e174","DOI":"10.3346\/jkms.2018.33.e174","volume":"33","author":"JO Shim","year":"2018","unstructured":"Shim JO, Han K, Park S, Kim GH, Ko JS, Chung JY. Ten-year Nationwide population-based survey on the characteristics of children with Henoch-Sch\u04e7nlein Purpura in Korea. J Korean Med Sci. 2018;33(25):e174. https:\/\/doi.org\/10.3346\/jkms.2018.33.e174.","journal-title":"J Korean Med Sci"},{"issue":"2","key":"3709_CR4","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/01.mpg.0000189369.45158.e3","volume":"43","author":"S Martin","year":"2006","unstructured":"Martin S, Cramer CH, Heikenen J, Gitomer JJ. Gastrointestinal symptoms of Henoch-Sch\u00f6nlein purpura treated with mycophenolate mofetil. J Pediatr Gastroenterol Nutr. 2006;43(2):245\u20137. https:\/\/doi.org\/10.1097\/01.mpg.0000189369.45158.e3.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"12","key":"3709_CR5","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1136\/ard.2006.069187","volume":"66","author":"J Aalberse","year":"2007","unstructured":"Aalberse J, Dolman K, Ramnath G, Pereira RR, Davin JC. Henoch Schonlein purpura in children: an epidemiological study among Dutch paediatricians on incidence and diagnostic criteria. Ann Rheum Dis. 2007;66(12):1648\u201350. https:\/\/doi.org\/10.1136\/ard.2006.069187.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"3709_CR6","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1067\/mge.2002.129592","volume":"56","author":"M Esaki","year":"2002","unstructured":"Esaki M, Matsumoto T, Nakamura S, Kawasaki M, Iwai K, Hirakawa K, et al. GI involvement in Henoch-Sch\u00f6nlein purpura. Gastrointest Endosc. 2002;56(6):920\u20133. https:\/\/doi.org\/10.1067\/mge.2002.129592.","journal-title":"Gastrointest Endosc"},{"key":"3709_CR7","doi-asserted-by":"publisher","first-page":"106229","DOI":"10.1016\/j.intimp.2020.106229","volume":"81","author":"Y Yu","year":"2020","unstructured":"Yu Y, Chen J, Yin H, Deng Z, Xie Y, Yuan Q, et al. Efficacy of steroid and immunosuppressant combined therapy in Chinese patients with Henoch-Sch\u00f6nlein purpura nephritis: a retrospective study. Int Immunopharmacol. 2020;81:106229. https:\/\/doi.org\/10.1016\/j.intimp.2020.106229.","journal-title":"Int Immunopharmacol"},{"issue":"9","key":"3709_CR8","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1136\/adc.2005.074641","volume":"90","author":"H Narchi","year":"2005","unstructured":"Narchi H. Risk of long term renal impairment and duration of follow up recommended for Henoch-Schonlein purpura with normal or minimal urinary findings: a systematic review. Arch Dis Child. 2005;90(9):916\u201320. https:\/\/doi.org\/10.1136\/adc.2005.074641.","journal-title":"Arch Dis Child"},{"issue":"11","key":"3709_CR9","doi-asserted-by":"publisher","first-page":"e0167346","DOI":"10.1371\/journal.pone.0167346","volume":"11","author":"H Chan","year":"2016","unstructured":"Chan H, Tang YL, Lv XH, Zhang GF, Wang M, Yang HP, et al. Risk factors associated with renal involvement in childhood Henoch-Sch\u00f6nlein Purpura: a meta-analysis. PLoS One. 2016;11(11):e0167346. https:\/\/doi.org\/10.1371\/journal.pone.0167346.","journal-title":"PLoS One"},{"key":"3709_CR10","unstructured":"Subspecialty Group of Immunology, Society of Pediatrics, Chinese Medical Association, Editorial Board of Chinese Journal of Pediatrics. Evidence-based recommendations for the diagnosis and management in the children with Henoch-Sch\u00f6nlein purpura. Zhonghua Er Ke Za Zhi. 2013;51(7):502\u20137."},{"issue":"12","key":"3709_CR11","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.autrev.2017.10.009","volume":"16","author":"MH Heineke","year":"2017","unstructured":"Heineke MH, Ballering AV, Jamin A, Ben MS, Monteiro RC, Van EM. New insights in the pathogenesis of immunoglobulin a vasculitis (Henoch-Sch\u00f6nlein purpura). Autoimmun Rev. 2017;16(12):1246\u201353. https:\/\/doi.org\/10.1016\/j.autrev.2017.10.009.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"3709_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s12519-014-0534-5","volume":"11","author":"JY Chen","year":"2015","unstructured":"Chen JY, Mao J. Henoch-Sch\u00f6nlein purpura nephritis in children: incidence, pathogenesis and management. World J Pediatr. 2015;11(1):29\u201334. https:\/\/doi.org\/10.1007\/s12519-014-0534-5.","journal-title":"World J Pediatr"},{"issue":"10","key":"3709_CR13","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1136\/archdischild-2013-303642","volume":"98","author":"J Dudley","year":"2013","unstructured":"Dudley J, Smith G, Llewelyn-Edwards A, Bayliss K, Pike K, Tizard J. Randomised, double-blind, placebo-controlled trial to determine whether steroids reduce the incidence and severity of nephropathy in Henoch-Schonlein Purpura (HSP). Arch Dis Child. 2013;98(10):756\u201363. https:\/\/doi.org\/10.1136\/archdischild-2013-303642.","journal-title":"Arch Dis Child"},{"issue":"10","key":"3709_CR14","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1007\/s00467-013-2550-4","volume":"8","author":"JC Davin","year":"2013","unstructured":"Davin JC, Coppo R. Pitfalls in recommending evidence-based guidelines for a protean disease like Henoch-Sch\u00f6nlein purpura nephritis. Pediatr Nephrol. 2013;8(10):1897\u2013903. https:\/\/doi.org\/10.1007\/s00467-013-2550-4.","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"3709_CR15","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1542\/peds.79.6.1018","volume":"79","author":"ND Rosenblum","year":"1987","unstructured":"Rosenblum ND, Winter HS. Steroid effects on the course of abdominal pain in children with Henoch-Schonlein purpura. Pediatrics. 1987;79(6):1018\u201321.","journal-title":"Pediatrics."},{"issue":"2 Suppl 89","key":"3709_CR16","first-page":"S-176-80","volume":"33","author":"\u00d6 Ba\u015faran","year":"2015","unstructured":"Ba\u015faran \u00d6, Cakar N, Uncu N, \u00c7elikel BA, Kara A, Cayci FS, et al. Plasma exchange therapy for severe gastrointestinal involvement of Henoch Sch\u00f6nlein purpura in children. Clin Exp Rheumatol. 2015;33(2 Suppl 89):S-176-80.","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"3709_CR17","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/ped.12670","volume":"57","author":"\u00dc Uluca","year":"2015","unstructured":"Uluca \u00dc, Ece A, \u015een V, Yel S, Tan \u0130, Karabel D. Management of intestinal bleeding with single-dose cyclophosphamide in Henoch-Sch\u00f6nlein purpura. Pediatr Int. 2015;57(3):498\u2013500. https:\/\/doi.org\/10.1111\/ped.12670.","journal-title":"Pediatr Int"},{"issue":"9","key":"3709_CR18","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1007\/s00431-020-03592-w","volume":"179","author":"H Wang","year":"2020","unstructured":"Wang H, Zhang B, Li S, Ou R, Liu Y, Tan W. Clinical outcome in pediatric refractory gastrointestinal Henoch-Sch\u00f6nlein purpura treated with mycophenolate mofetil. Eur J Pediatr. 2020;179(9):1361\u20136. https:\/\/doi.org\/10.1007\/s00431-020-03592-w.","journal-title":"Eur J Pediatr"},{"issue":"1","key":"3709_CR19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12969-018-0285-2","volume":"16","author":"CB Crayne","year":"2018","unstructured":"Crayne CB, Eloseily E, Mannion ML, Azerf SP, Weiser P, Beukelman T, et al. Rituximab treatment for chronic steroid-dependent Henoch-Schonlein purpura: 8 cases and a review of the literature. Pediatr Rheumatol Online J. 2018;16(1):71. https:\/\/doi.org\/10.1186\/s12969-018-0285-2.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"6","key":"3709_CR20","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.arcped.2016.03.018","volume":"23","author":"B Cherqaoui","year":"2016","unstructured":"Cherqaoui B, Chausset A, Stephan JL, Merlin E. Intravenous immunoglobulins for severe gastrointestinal involvement in pediatric Henoch-Sch\u00f6nlein purpura: a French retrospective study. Arch Pediatr. 2016;23(6):584\u201390. https:\/\/doi.org\/10.1016\/j.arcped.2016.03.018.","journal-title":"Arch Pediatr"},{"issue":"1","key":"3709_CR21","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1186\/s12887-019-1802-2","volume":"19","author":"Y Zhu","year":"2019","unstructured":"Zhu Y, Dong Y, Wu L, Deng F. Changes of inflammatory mediators and oxidative stress indicators in children with Henoch-Sch\u00f6nlein purpura and clinical effects of hemoperfusion in the treatment of severe Henoch-Sch\u00f6nlein purpura with gastrointestinal involvement in children. BMC Pediatr. 2019;19(1):409. https:\/\/doi.org\/10.1186\/s12887-019-1802-2.","journal-title":"BMC Pediatr"},{"issue":"7","key":"3709_CR22","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1136\/ard.2005.046300","volume":"65","author":"S Ozen","year":"2006","unstructured":"Ozen S, Ruperto N, Dillon MJ, Bagga A, Barron K, Davin JC, et al. EULAR\/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis. 2006;65(7):936\u201341. https:\/\/doi.org\/10.1136\/ard.2005.046300.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"3709_CR23","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1136\/ard.2009.116657","volume":"69","author":"S Ozen","year":"2010","unstructured":"Ozen S, Pistorio A, Iusan SM, Bakkaloglu A, Herlin T, Brik R, et al. EULAR\/PRINTO\/PRES criteria for Henoch-Sch\u00f6nlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: final classification criteria. Ann Rheum Dis. 2010;69(5):798\u2013806. https:\/\/doi.org\/10.1136\/ard.2009.116657.","journal-title":"Ann Rheum Dis"},{"key":"3709_CR24","doi-asserted-by":"publisher","first-page":"254316","DOI":"10.1155\/2010\/254316","volume":"2010","author":"AA Nikibakhsh","year":"2010","unstructured":"Nikibakhsh AA, Mahmoodzadeh H, Karamyyar M, Hejazi S, Noroozi M, Macooie AA, et al. Treatment of complicated henoch-sch\u00f6nlein purpura with mycophenolate mofetil: a retrospective case series report. Int J Rheumatol. 2010;2010:254316. https:\/\/doi.org\/10.1155\/2010\/254316.","journal-title":"Int J Rheumatol"},{"issue":"7","key":"3709_CR25","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s00467-017-3608-5","volume":"32","author":"M Koskela","year":"2017","unstructured":"Koskela M, Ylinen E, Ukonmaanaho EM, Autio-Harmainen H, Heikkil\u00e4 P, Lohi J, et al. The ISKDC classification and a new semiquantitative classification for predicting outcomes of Henoch-Sch\u00f6nlein purpura nephritis. Pediatr Nephrol. 2017;32(7):1201\u20139. https:\/\/doi.org\/10.1007\/s00467-017-3608-5.","journal-title":"Pediatr Nephrol"},{"key":"3709_CR26","doi-asserted-by":"publisher","unstructured":"Subspecialty Group of Renal Diseases, the Society of Pediatrics, Chinese Medical Association. Evidence-based guideline for diagnosis and treatment of Henoch-Schonlein purpura nephritis (2016). Zhonghua Er Ke Za Zhi. 2017;55(9):647\u201351. https:\/\/doi.org\/10.3760\/cma.j.issn.0578-1310.2017.09.003.","DOI":"10.3760\/cma.j.issn.0578-1310.2017.09.003"},{"key":"3709_CR27","unstructured":"Subspecialty Group of Nephrology, Society of Pediatrics, Chinese Medical Association. Evidence-based guidelines on diagnosis and treatment of childhood common renal diseases (II): evidence-based guideline on diagnosis and treatment of Henoch-Schonlein purpura nephritis. Zhonghua Er Ke Za Zhi. 2009;47(12):911\u20133."},{"issue":"1","key":"3709_CR28","first-page":"e67","volume":"8","author":"S Safari","year":"2020","unstructured":"Safari S, Salimi A, Zali A, Jahangirifard A, Bastanhagh E, Aminnejad R, et al. Extracorporeal Hemoperfusion as a potential therapeutic option for severe COVID-19 patients; a narrative review. Arch Acad Emerg Med. 2020;8(1):e67.","journal-title":"Arch Acad Emerg Med"},{"issue":"17","key":"3709_CR29","first-page":"3894","volume":"21","author":"DQ Ma","year":"2017","unstructured":"Ma DQ, Li Y, Han ZG, Zheng M, Xu N, Fan XJ. Analysis on kidney injury-related clinical risk factors and evaluation on the therapeutic effects of hemoperfusion in children with Henoch-Schonlein purpura. Eur Rev Med Pharmacol Sci. 2017;21(17):3894\u20139.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"5","key":"3709_CR30","doi-asserted-by":"publisher","first-page":"378","DOI":"10.7499\/j.issn.1008-8830.2018.05.008","volume":"20","author":"Y Zhu","year":"2018","unstructured":"Zhu Y, Dong Y, Xu DL, Jiang JY, Wu L, Ke RJ, et al. Clinical effect and mechanism of hemoperfusion in treatment of children with severe abdominal Henoch-Sch\u00f6nlein purpura. Zhongguo Dang Dai Er Ke Za Zhi. 2018;20(5):378\u201382. https:\/\/doi.org\/10.7499\/j.issn.1008-8830.2018.05.008.","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi"},{"issue":"7","key":"3709_CR31","doi-asserted-by":"publisher","first-page":"489","DOI":"10.5301\/ijao.5000223","volume":"36","author":"L Chen","year":"2013","unstructured":"Chen L, Wang Z, Zhai S, Zhang H, Lu J, Chen X. Effects of hemoperfusion in the treatment of childhood Henoch-Sch\u00f6nlein purpura nephritis. Int J Artif Organs. 2013;36(7):489\u201397. https:\/\/doi.org\/10.5301\/ijao.5000223.","journal-title":"Int J Artif Organs"},{"issue":"4","key":"3709_CR32","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00467-019-04415-3","volume":"35","author":"M Koskela","year":"2020","unstructured":"Koskela M, Ylinen E, Autio-Harmainen H, Tokola H, Heikkil\u00e4 P, Lohi J, et al. Prediction of renal outcome in Henoch-Sch\u00f6nlein nephritis based on biopsy findings. Pediatr Nephrol. 2020 Dec;35(4):659\u201368. https:\/\/doi.org\/10.1007\/s00467-019-04415-3.","journal-title":"Pediatr Nephrol"},{"issue":"12","key":"3709_CR33","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1111\/jpc.12403","volume":"49","author":"P Trnka","year":"2013","unstructured":"Trnka P. Henoch-Schonlein purpura in children. J Paediatr Child Health. 2013;49(12):995\u20131003. https:\/\/doi.org\/10.1111\/jpc.12403.","journal-title":"J Paediatr Child Health"},{"issue":"3","key":"3709_CR34","doi-asserted-by":"publisher","first-page":"66","DOI":"10.4329\/wjr.v7.i3.66","volume":"7","author":"P Prathiba Rajalakshmi","year":"2015","unstructured":"Prathiba Rajalakshmi P, Srinivasan K. Gastrointestinal manifestations of Henoch-Schonlein purpura: a report of two cases. World J Radiol. 2015;7(3):66\u20139. https:\/\/doi.org\/10.4329\/wjr.v7.i3.66.","journal-title":"World J Radiol"},{"issue":"7","key":"3709_CR35","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s10157-019-01726-5","volume":"23","author":"EK \u00c7ak\u0131c\u0131","year":"2019","unstructured":"\u00c7ak\u0131c\u0131 EK, G\u00fcr G, Yaz\u0131l\u0131ta\u015f F, Ero\u011flu FK, G\u00fcng\u00f6r T, Arda N, et al. A retrospective analysis of children with Henoch-Schonlein purpura and re-evaluation of renal pathologies using Oxford classification. Clin Exp Nephrol. 2019;23(7):939\u201347. https:\/\/doi.org\/10.1007\/s10157-019-01726-5.","journal-title":"Clin Exp Nephrol"},{"issue":"12","key":"3709_CR36","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1111\/j.1651-2227.2009.01445.x","volume":"98","author":"R Bogdanovi\u0107","year":"2009","unstructured":"Bogdanovi\u0107 R. Henoch-Sch\u00f6nlein purpura nephritis in children: risk factors, prevention and treatment. Acta Paediatr. 2009;98(12):1882\u20139. https:\/\/doi.org\/10.1111\/j.1651-2227.2009.01445.x.","journal-title":"Acta Paediatr"},{"issue":"5","key":"3709_CR37","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s10067-017-3972-3","volume":"37","author":"IM Buscatti","year":"2018","unstructured":"Buscatti IM, Casella BB, Aikawa NE, Watanabe A, Farhat SCL, Campos LMA, et al. Henoch- Sch\u00f6nlein purpura nephritis: initial risk factors and outcomes in a Latin American tertiary center. Clin Rheumatol. 2018;37(5):1319\u201324. https:\/\/doi.org\/10.1007\/s10067-017-3972-3.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"3709_CR38","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3760\/cma.j.issn.0253-2727.2017.01.013","volume":"38","author":"N Zhang","year":"2017","unstructured":"Zhang N, Guo PJ, Liu PL, Yang HR, Xiao J, Li XP, et al. Comparison of age-based clinical and abnormal immune parameters in patients with Henoch-Sch\u00f6nlein purpura. Zhonghua Xue Ye Xue Za Zhi. 2017;38(1):60\u20134. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2017.01.013.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"4","key":"3709_CR39","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1007\/s00431-002-0922-z","volume":"161","author":"H Sano","year":"2002","unstructured":"Sano H, Izumida M, Shimizu H, Ogawa Y. Risk factors of renal involvement and significant proteinuria in Henoch-Sch\u00f6nlein purpura. Eur J Pediatr. 2002;161(4):196\u2013201. https:\/\/doi.org\/10.1007\/s00431-002-0922-z.","journal-title":"Eur J Pediatr"},{"issue":"11","key":"3709_CR40","doi-asserted-by":"publisher","first-page":"e0188718","DOI":"10.1371\/journal.pone.0188718","volume":"12","author":"E Pillebout","year":"2017","unstructured":"Pillebout E, Jamin A, Ayari H, Housset P, Pierre M, Sauvaget V, et al. Biomarkers of IgA vasculitis nephritis in children. PLoS One. 2017;12(11):e0188718. https:\/\/doi.org\/10.1371\/journal.pone.0188718.","journal-title":"PLoS One"},{"issue":"9","key":"3709_CR41","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1093\/ndt\/gfx300","volume":"33","author":"L Berthelot","year":"2017","unstructured":"Berthelot L, Jamin A, Viglietti D, Chemouny JM, Ayari H, Pierre M, et al. Value of biomarkers for predicting immunoglobulin a vasculitis nephritis outcome in an adult prospective cohort. Nephrol Dial Transplant. 2017;33(9):1579\u201390. https:\/\/doi.org\/10.1093\/ndt\/gfx300.","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"3709_CR42","doi-asserted-by":"publisher","first-page":"175","DOI":"10.5223\/pghn.2016.19.3.175","volume":"19","author":"YH Lee","year":"2016","unstructured":"Lee YH, Kim YB, Koo JW, Chung JY. Henoch-Schonlein Purpura in children hospitalized at a tertiary hospital during 2004-2015 in Korea: epidemiology and clinical management. Pediatr Gastroenterol Hepatol Nutr. 2016;19(3):175\u201385. https:\/\/doi.org\/10.5223\/pghn.2016.19.3.175.","journal-title":"Pediatr Gastroenterol Hepatol Nutr"},{"issue":"9","key":"3709_CR43","first-page":"918","volume":"17","author":"Y Mu","year":"2015","unstructured":"Mu Y, Sun C, Wang L, Meng DM, Sun XG. Values of different biomarkers for diagnosis of Henoch-Sch\u00f6nlein purpura in children. Zhongguo Dang Dai Er Ke Za Zhi. 2015;17(9):918\u201321.","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi"},{"issue":"1","key":"3709_CR44","doi-asserted-by":"publisher","first-page":"72","DOI":"10.11817\/j.issn.1672-7347.2017.01.012","volume":"42","author":"L Zhao","year":"2017","unstructured":"Zhao L, Li Y. Retrospective analysis on 337 cases of Henoch-Sch\u00f6nlein purpura. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2017;42(1):72\u20137. https:\/\/doi.org\/10.11817\/j.issn.1672-7347.2017.01.012.","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban"},{"key":"3709_CR45","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.clinbiochem.2017.11.006","volume":"52","author":"N Purevdorj","year":"2017","unstructured":"Purevdorj N, Mu Y, Gu Y, Zheng F, Wang R, Yu J, et al. Clinical significance of the serum biomarker index detection in children with Henoch-Schonlein purpura. Clin Biochem. 2017;52:167\u201370. https:\/\/doi.org\/10.1016\/j.clinbiochem.2017.11.006.","journal-title":"Clin Biochem"},{"issue":"11","key":"3709_CR46","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1093\/intimm\/dxx039","volume":"29","author":"C Galeotti","year":"2017","unstructured":"Galeotti C, Kaveri SV, Bayry J. IVIG-mediated effector functions in autoimmune and inflammatory diseases. Int Immunol. 2017;29(11):491\u20138. https:\/\/doi.org\/10.1093\/intimm\/dxx039.","journal-title":"Int Immunol"},{"issue":"6","key":"3709_CR47","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1093\/rheumatology\/keq021","volume":"49","author":"PM Vaitla","year":"2010","unstructured":"Vaitla PM, McDermott EM. The role of high-dose intravenous immunoglobulin in rheumatology. Rheumatology (Oxford). 2010;49(6):1040\u20138. https:\/\/doi.org\/10.1093\/rheumatology\/keq021.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"3709_CR48","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.1111\/pde.13715","volume":"36","author":"A Mauro","year":"2019","unstructured":"Mauro A, Mauro S, Rega R, Martemucci L, Sottile R. Successful treatment of hemorrhagic bullous Henoch-Schonlein purpura with intravenous immunoglobulins. Pediatr Dermatol. 2019;36(1):e34\u20136. https:\/\/doi.org\/10.1111\/pde.13715.","journal-title":"Pediatr Dermatol"},{"issue":"9","key":"3709_CR49","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s00431-006-0337-3","volume":"166","author":"AA Fagbemi","year":"2007","unstructured":"Fagbemi AA, Torrente F, Hilson AJ, Thomson MA, Heuschkel RB, Murch SH. Massive gastrointestinal haemorrhage in isolated intestinal Henoch-Schonlein purpura with response to intravenous immunoglobulin infusion. Eur J Pediatr. 2007;166(9):915\u20139. https:\/\/doi.org\/10.1007\/s00431-006-0337-3.","journal-title":"Eur J Pediatr"},{"issue":"9","key":"3709_CR50","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1007\/s00296-012-2474-5","volume":"33","author":"MF De","year":"2013","unstructured":"De MF, Dinardo R, Buonocore MC, Dinardo M, Bartolomei B, Rigante D. Intravenous immunoglobulin in Henoch-Sch\u00f6nlein purpura complicated by cerebral hemorrhage. Rheumatol Int. 2013;33(9):2451\u20133. https:\/\/doi.org\/10.1007\/s00296-012-2474-5.","journal-title":"Rheumatol Int"},{"issue":"8","key":"3709_CR51","doi-asserted-by":"publisher","first-page":"796","DOI":"10.5301\/ijao.5000223","volume":"17","author":"L Liu","year":"2015","unstructured":"Liu L, Huang YP, Fang XL, Zhang YY, Chen N, Hou HH. Effects of hemoperfusion treatment on serum IL-23 and IL-17 levels in children with Henoch-Sch\u00f6nlein purpure. Zhongguo Dang Dai Er Ke Za Zhi. 2015;17(8):796\u20139. https:\/\/doi.org\/10.5301\/ijao.5000223.","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-022-03709-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12887-022-03709-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-022-03709-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T10:31:55Z","timestamp":1669977115000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpediatr.biomedcentral.com\/articles\/10.1186\/s12887-022-03709-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,2]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3709"],"URL":"https:\/\/doi.org\/10.1186\/s12887-022-03709-0","relation":{},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,2]]},"assertion":[{"value":"7 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the principles outlined in the Declaration of Helsinki with approval from the ethics committee of Children\u2019s Hospital of Nanjing Medical University (reference number: 202206126-1). We have concealed the patients\u2019 private information in this retrospective study, such as name, address, contact information, etc. The informed consent waiver was approved by the institutional review board of Children\u2019s Hospital of Nanjing Medical University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"692"}}